This article is more than 5 years old. Information may no longer be current.
Sight Sciences financing to support Omni, TearCare systems
Sight Sciences has closed $31 million in Series D preferred stock financing in order to accelerate the growth of its Omni surgical system and TearCare system in the United States, according to a press release.
Funding was led by KCK Group, with participation from MidCap Financial.
Earlier this year, MidCap and Sight Sciences entered into a $25 million debt facility, bringing the total financing proceeds to $56 million.
“We could not be more thrilled than to have KCK as our lead growth equity investor and MidCap as our debt capital provider,” Jesse Selnick, chief financial officer of Sight Sciences, said in the release. “KCK’s unmatched breadth of high growth medtech investment and operating experience, which includes successful and disruptive market development work, is truly the perfect match for where we are in our company’s evolution. We look forward to long and successful partnerships with our key stakeholders and to continue upon the substantial commercial and product development progress Sight Sciences has made over the past year.”